R3 C511
Indianapolis, IN 46202
Bio
Dr. Xiumei Huang is a tenure-track Assistant Professor in the Department of Radiation Oncology and full member of Indiana University Simon Comprehensive Cancer Center. Prior to her appointment at Indiana University in January 2018, she received her Ph.D. training in neuroscience from Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA). Dr. Huang completed her postdoctoral training in chemotherapy, radiotherapy and immunotherapy for cancer at UT Southwestern Medical Center/Simmons Comprehensive Cancer Center (Dallas, TX).
Dr. Huang's lab is currently invovled in three broad areas of research. The first area focuses on understanding the mechanisms of tumor-selective radiosensitization of Non-Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC) and Pancreatic Ductal Adenocarcinoma (PDA) using novel NQO1 bioactivatable drugs. The second area centers on screening novel NQO1 bioactivatable drugs and uncovering the mechanisms underlying the synergy between these drugs and PARP inhibitors. Lastly, the third area investigates the mechanisms by which NQO1 bioactivatable drugs stimulate innate and adaptive immunity.
Current Research Funding
NIH R01CA240952-03 (Huang, PI), Targeting NQO1+ tumor to trigger innate and adaptive immunity.
NIH 1R01CA224493-05 (Huang, PI), Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs.
NIH 5R01CA221158-06 (Huang & Motea, MPI), Tumor-selective use of PARP inhibitors against NQO1+ non-small cell lung cancer.
Current Lab Members Related Link: Huang Lab
Postdoctoral fellows:
Lingxiang Jiang, Ph.D.
Soumya Tumbath, Ph.D.
Key Publications
Selected publications:
Corresponding author’s publications
- Wang J, Su X, Jiang L, Boudreau MW, Chatkewitz LE, Kilgore JA, Zahid KR, Williams NS, Chen Y, Liu S, Hergenrother PJ# and Huang X#. Augmented Concentration of Isopentyl-Deoxynyboquinone in Tumors Selectively Kills NAD(P)H Quinone Oxidoreductase 1-Positve Cancer Cells through Programmed Necrotic and Apoptotic Mechanisms. Cancers, 2023, 15:5844.
- Jiang L, Liu Y, Tumbath S, Boudreau MW, Chatkewitz LE, Wang J, Su X, Zahid KR, Li K, Chen Y, Yang K, Hergenrother PJ# and Huang X#. IP-DNQ induces mitochondrial dysfunction and G2/M phase cell cycle arrest to selectively kill NQO1-positive pancreatic cancer cells. Antioxidants & Redox Signaling, 2023 Nov 11.
- Jiang L, Liu Y, Su X, Wang J, Tumbath S, Zhao Y, Kilgore JA, Williams NS, Chen Y, Wang X, Mendonca MS, Lu T, Fu YX and Huang X#. KP372-1-induced AKT Hyperactivation Blocks DNA Repair to Synergize with PARP inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway. Frontiers in Oncology, 2022, 12:976292.
- Zahid KR, Raza U, Tumbath S, Jiang L, Xu W and Huang X#. Neutrophils: Musketeers against immunotherapy. Frontiers in Oncology, 2022, 12:975981.
- Zhao W, Jiang L, Fang T, Fang F, Liu Y, Zhao Y, You Y, Zhou H, Su X, Wang J, Liu S, Chen Y, Wan J and Huang X#. β-lapachone selectively kills hepatocellular carcinoma cells by targeting NQO1 to induce extensive DNA damage and PARP1 hyperactivation. Frontiers in Oncology, 2021, 11:747282.
- Su X, Wang J, Jiang L, Chen Y, Lu T, Mendonca MS and Huang X#. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage. Cancer Letters, 2021, 519:304-314.
- Li X, Liu Z, Zhang A, Han C, Shen A, Jiang L, Boothman DA, Qiao J, Wang Y, Huang X# and Fu YX#. NQO1 targeting prodrug triggers innate sensing and overcomes checkpoint blockade resistance. Nature Communications, 2019, 19;10(1):3251. (#Co-corresponding authors).
First or Co-first author's publications
- Motea EA*, Huang X*, Singh N, Kilgore JA, Williams NS, Xie X, Gerber DE, Beg MS, Bey EA and Boothman DA. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers. Clinical Cancer Research, 2019, 25(8): 2601-2609. (*Co-first authors).
- Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, and Boothman DA. Leveraging an NQO1 bioactivatable drug for tumor-selective use of Poly(ADP-ribose) polymerase (PARP) inhibitors. Cancer Cell, 2016, 30: 940-952.
- Ma X*, Huang X*, Moore Z, Huang G, Kilgore JA, Wang Y, Hammer S, Williams NS, Boothman DA, Gao J. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy. Journal of Controlled Release, 2015, 200: 201-211. (*Co-first authors).
- Chen Y*, Huang X*, Zhang YW, Rockenstein E, Bu G, Masliah E, Golde TE, Xu H. Alzheimer’s β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid. The Journal of Neuroscience, 2012, 32(33): 11390-11395. (*Co-first authors).
- Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, Patel M, Parkinson EI, Wang Y, Williams NS, Gao J, Hergenrother PJ, Boothman DA. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Research, 2012,72(12): 3038-3047.
- Huang X, Chen Y, Zhang H, Ma Q, Zhang YW, Xu H. Salubrinal attenuates amyloid β-induced neuronal death and microglial activation by inhibition of the NF-κB pathway. Neurobiology of Aging, 2012, 33(5): 1007.e9-1007.e17.
- Chen Y*, Huang X*, Thompson R, Zhao YB. Clinical features and efficacy of escitalopram treatment for geriatric depression. Journal of International Medical Research, 2011, 39(5): 1946-1953. (*Co-first authors).
- Huang X, Chen Y, Li WB, Cohen SN, Liao FF, Li L, Xu H, Zhang YW. The Rps23rg gene family originated through retroposition of the ribosomal protein s23 mRNA and encodes proteins that decrease Alzheimer's β-amyloid level and tau phosphorylation. Human Molecular Genetics, 2010, 19(19): 3835-3843.
Titles & Appointments
- Assistant Professor of Radiation Oncology
-
Education
-
Research
-
Professional Organizations